KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Johnson & Johnson (JNJ) Capital Expenditures (2016 - 2025)

Johnson & Johnson's Capital Expenditures history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 13.96% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $4.8 billion, up 9.22%, while the annual FY2025 figure was $4.8 billion, 9.22% up from the prior year.
  • Capital Expenditures for Q4 2025 was $1.8 billion at Johnson & Johnson, up from $1.2 billion in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.8 billion in Q4 2025 and bottomed at $607.0 million in Q2 2022.
  • The 5-year median for Capital Expenditures is $1.0 billion (2024), against an average of $1.1 billion.
  • The largest annual shift saw Capital Expenditures surged 42.17% in 2023 before it dropped 13.17% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $747.0 million in 2021, then fell by 18.74% to $607.0 million in 2022, then surged by 161.78% to $1.6 billion in 2023, then grew by 1.45% to $1.6 billion in 2024, then grew by 13.96% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for JNJ's Capital Expenditures are $1.8 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.0 billion (Q2 2025).